Literature DB >> 23563208

Surgery for Li Fraumeni syndrome: pushing the limits of surgical oncology.

Russell C Langan1, Kiran H Lagisetty, Scott Atay, Prakash Pandalai, Alexander Stojadinovic, Udo Rudloff, Itzhak Avital.   

Abstract

OBJECTIVES: Li Fraumeni syndrome is an autosomal dominant cancer syndrome due to a germline mutation in the p53 tumor suppressor gene. It results in multiple primary neoplasms in children and adults. A common question when faced with a Li Fraumeni patient who develops multiple primary cancers and/or recurrences is what is the proper treatment? Data suggests that ionizing radiation exposure increases the incidence of second malignancies in the Li Fraumeni population. Therefore, how much surgery can a cancer patient tolerate and still derive benefit from it?
METHODS: We describe a representative case of a 54-year-old female with Li Fraumeni syndrome with an enlarging adrenocortical hepatic metastasis, a new primary ampullary cancer, and an extensive surgical history.
RESULTS: We performed a simultaneous pancreaticoduodenectomy and repeat partial hepatectomy.
CONCLUSIONS: We propose that surgery is underutilized in metastatic solid organ familial cancers in general, and argue that an aggressive surgical approach should be considered in a multidisciplinary manner for patients with Li Fraumeni syndrome and recurrent tumors. However, because of the rarity of this familial cancer there is a paucity of evidence to support this approach, therefore a review of the literature is presented.

Entities:  

Mesh:

Year:  2015        PMID: 23563208      PMCID: PMC3731398          DOI: 10.1097/COC.0b013e3182880bc5

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  23 in total

1.  Sensitivity and predictive value of criteria for p53 germline mutation screening.

Authors:  A Chompret; A Abel; D Stoppa-Lyonnet; L Brugiéres; S Pagés; J Feunteun; C Bonaïti-Pellié
Journal:  J Med Genet       Date:  2001-01       Impact factor: 6.318

2.  Multiple primary cancers in families with Li-Fraumeni syndrome.

Authors:  M Hisada; J E Garber; C Y Fung; J F Fraumeni; F P Li
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

3.  Multiple primary cutaneous melanomas in Li-Fraumeni syndrome.

Authors:  Clara Curiel-Lewandrowski; Larisa Sotinsky Speetzen; Lee Cranmer; James A Warneke; Lois J Loescher
Journal:  Arch Dermatol       Date:  2011-02

4.  Basic principles in surgical oncology.

Authors:  B Cady
Journal:  Arch Surg       Date:  1997-04

5.  Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.

Authors:  J M Limacher; T Frebourg; S Natarajan-Ame; J P Bergerat
Journal:  Int J Cancer       Date:  2001-08-20       Impact factor: 7.396

6.  p53 expression in three separate tumours from a patient with Li-Fraumeni's syndrome.

Authors:  P King; A W Craft; A J Malcolm
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

7.  The first case of Li-Fraumeni syndrome in Bosnia and Herzegovina: case report.

Authors:  S Vranic; L Kapur; F Foco; N Bilalovic; P Hainaut
Journal:  Pathologica       Date:  2006-04

8.  Liver resection and ablation for metastatic adrenocortical carcinoma.

Authors:  R Taylor Ripley; Clinton D Kemp; Jeremy L Davis; Russell C Langan; Richard E Royal; Steven K Libutti; Seth M Steinberg; Bradford J Wood; Udai S Kammula; Tito Fojo; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2011-02-08       Impact factor: 5.344

9.  Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.

Authors:  A Salmon; D Amikam; N Sodha; S Davidson; L Basel-Vanagaite; R A Eeles; D Abeliovich; T Peretz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-06-14       Impact factor: 4.126

10.  Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice.

Authors:  R E J Mitchel; J S Jackson; S M Carlisle
Journal:  Radiat Res       Date:  2004-07       Impact factor: 2.841

View more
  1 in total

Review 1.  Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy.

Authors:  Brian F Chapin
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.